Overview
Safety
Science
Debate
Protocol
Safety Triggers
Focus / ADHD
Known safety concerns, contraindications, and risk factors.
FDA Category 2 Prohibition — Semax, Selank and Peer Peptides
Critical
Dihexa Oncogenic Risk — HGF/c-Met Pathway Activation
Critical
Cerebrolysin — Renal Failure Contraindication
Critical
Pregnancy and Nursing — Blanket Contraindication
Critical
Selank Immunogenicity — Neutralising Antibody Formation
Severe
Receptor Downregulation with Chronic Semax/Selank Use
Severe
Grey-Market Peptide Contamination
Severe
Cerebrolysin — Microbial Growth After Ampoule Opening
Severe
Psychiatric Instability — Semax, Selank, Rhodiola in Mood Disorders
Severe
Zinc–Copper Depletion with Chronic High-Dose Supplementation
Moderate
Drug Interactions — MAOIs, SSRIs, L-Dopa, Anticoagulants
Moderate
Noopept Overstimulation — Sleep Disruption and Blood Pressure
Moderate
Safety Triggers — Focus / ADHD | pin.board